Several cases discuss the decision-making process regarding whether treatment should be considered for the advanced stage of age-related macular degeneration and whether that treatment should include ranibizumab, bevacizumab, or another therapy. In addition, decisions regarding need for additional treatment at follow-up and the approach to follow-up are discussed with these cases.

This podcast presents an overview of the clinical manifestations of the early, intermediate, and advanced stages of age-related macular degeneration. The prevalence and incidence of the intermediate and advanced stages of age-related macular degeneration and their impact on quality of life is also discussed. Particular attention is paid to the results of a study that compares the impact of the neovascular form of age-related macular degeneration on preference values relative to other chronic diseases.

Dr. Trese discusses the impact of adding dietary supplements and how they can affect the progression of disease.

Dr. Bressler discusses the variables involved in the follow-up treatment of neovascular age-related macular degeneration once.

In the context of AMD, Dr. Nancy Holekamp discusses the treatment of extrafoveal and some juxtafoveal choroidal neovascular lesions, the management of predominantly classic compared with minimally classic or occult with no classic choroidal neovascularization, and quality-of-life outcomes following anti-VEGF therapy.

Dr. Bressler presents an overview of the program, including how the program originated. He also discusses the role of educational grants and defines fair-balance in this context.